CHENGUANG BIOTECH GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.97 CNY | +2.05% |
|
+5.50% | -25.76% |
| 04-24 | ChenGuang Biotech Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-24 | ChenGuang Biotech Group Co., Ltd.announces an Increase in Equity Buyback. | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,829 | 9,222 | 8,897 | 9,446 | 7,155 | 5,111 | - | - |
| Enterprise Value (EV) 1 | 3,829 | 9,222 | 8,897 | 11,136 | 9,965 | 6,631 | 6,435 | 5,111 |
| P/E ratio | 19.7 x | 35.5 x | 24.9 x | 21.8 x | 14.9 x | 13.5 x | 8.05 x | 7.58 x |
| Yield | - | 0.52% | 0.78% | 0.9% | 0.97% | 1.72% | 2.17% | - |
| Capitalization / Revenue | 1.17 x | 2.34 x | 1.83 x | 1.5 x | 1.04 x | 0.71 x | 0.58 x | 0.54 x |
| EV / Revenue | 1.17 x | 2.34 x | 1.83 x | 1.77 x | 1.45 x | 0.92 x | 0.73 x | 0.54 x |
| EV / EBITDA | - | 21.8 x | 17.3 x | 17.6 x | 14.2 x | 10.4 x | 6.56 x | 4.67 x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | - | 4.82 x | 3.19 x | 2.98 x | 2.06 x | 1.41 x | 1.16 x | 1.11 x |
| Nbr of stocks (in thousands) | 511,868 | 481,561 | 532,774 | 532,774 | 532,774 | 512,601 | - | - |
| Reference price 2 | 7.480 | 19.15 | 16.70 | 17.73 | 13.43 | 9.970 | 9.970 | 9.970 |
| Announcement Date | 20-02-28 | 21-02-26 | 22-02-28 | 23-02-28 | 24-02-01 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3,267 | 3,934 | 4,874 | 6,296 | 6,872 | 7,237 | 8,843 | 9,478 |
| EBITDA 1 | - | 423.5 | 515.7 | 632.2 | 701.1 | 636.1 | 981.2 | 1,094 |
| EBIT 1 | - | 311.2 | 384.9 | 487 | 548.3 | 441.3 | 734.5 | 787.8 |
| Operating Margin | - | 7.91% | 7.9% | 7.74% | 7.98% | 6.1% | 8.31% | 8.31% |
| Earnings before Tax (EBT) 1 | - | 313.3 | 398.1 | 501.8 | 555.8 | 467.8 | 770.4 | 815.3 |
| Net income 1 | - | 270.3 | 351.5 | 434 | 479.7 | 392.6 | 659.5 | 699.1 |
| Net margin | - | 6.87% | 7.21% | 6.89% | 6.98% | 5.43% | 7.46% | 7.38% |
| EPS 2 | 0.3800 | 0.5400 | 0.6700 | 0.8147 | 0.9017 | 0.7374 | 1.238 | 1.315 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | 0.1000 | 0.1300 | 0.1600 | 0.1300 | 0.1713 | 0.2162 | - |
| Announcement Date | 20-02-28 | 21-02-26 | 22-02-28 | 23-02-28 | 24-02-01 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q1 | 2022 Q2 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales | 1,585 | 1,642 | 1,500 | - | 1,851 | 1,702 | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT | 117 | 144 | 110.2 | - | 199.6 | 83.5 | - | - | - | - |
| Operating Margin | 7.38% | 8.77% | 7.35% | - | 10.78% | 4.91% | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | 84.67 | - | - | - | - |
| Net income | - | - | - | 135 | - | 81.37 | - | - | - | - |
| Net margin | - | - | - | - | - | 4.78% | - | - | - | - |
| EPS | 0.2007 | 0.2500 | 0.1800 | 0.2535 | 0.3100 | 0.1500 | - | - | - | - |
| Dividend per Share 1 | - | - | 0.1600 | - | - | - | - | - | - | 0.1713 |
| Announcement Date | 22-04-25 | 22-08-22 | 23-02-28 | 23-04-25 | 23-08-13 | 24-02-01 | - | - | - | - |
1CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 1,690 | 2,809 | 1,520 | 1,324 | - |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | 2.672 x | 4.007 x | 2.389 x | 1.349 x | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | 14.4% | 13.7% | 14.6% | 14.3% | 10.6% | 14.5% | 14.7% |
| ROA (Net income/ Total Assets) | - | 5.9% | 6.63% | - | 6.28% | 4.1% | 6.9% | 7.8% |
| Assets 1 | - | 4,579 | 5,305 | - | 7,644 | 9,576 | 9,557 | 8,963 |
| Book Value Per Share 2 | - | 3.970 | 5.230 | 5.940 | 6.510 | 7.070 | 8.570 | 8.990 |
| Cash Flow per Share 2 | - | 1.020 | 0.1200 | 1.380 | -1.100 | 1.460 | -0.7400 | 2.340 |
| Capex 1 | - | 436 | 277 | 176 | 189 | 240 | 292 | 286 |
| Capex / Sales | - | 11.08% | 5.69% | 2.79% | 2.75% | 3.32% | 3.3% | 3.02% |
| Announcement Date | 20-02-28 | 21-02-26 | 22-02-28 | 23-02-28 | 24-02-01 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
9.97
CNY
Average target price
17.31
CNY
Spread / Average Target
+73.65%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -25.76% | 708M | |
| -5.49% | 266B | |
| -2.13% | 95.09B | |
| -3.16% | 43.48B | |
| +0.07% | 40.63B | |
| +6.29% | 40.07B | |
| +7.32% | 39.47B | |
| -14.72% | 30.45B | |
| -5.71% | 28.98B | |
| +13.52% | 25.18B |
- Stock Market
- Equities
- 300138 Stock
- Financials ChenGuang Biotech Group Co., Ltd.